professionals are saying

Tell us about your project

Be contacted

MEDIA

PML_Valerie-Chevreul_Laureat-Prix-EY_Press-release_2026
8 October 2026

Lemer Pax in the spotlight: Pierre-Marie Lemer and Valérie Chevreul, winners of the 2026 EY Entrepreneur of the Year Award – West region – France

Carquefou – 08.10.2026 On the occasion of the 34th edition of EY’s Entrepreneur of the Year Award, held at the MeM in Rennes (France), Pierre-Marie Lemer, President of Lemer Pax, and Valérie Chevreul, Chief Executive Officer, were honoured by receiving...
CDMO and Radiopharmaceuticals Lemer Pax
11 July 2026

CDMO and Radiopharmaceuticals: What is a production line and How is it equipped?

The production of radiopharmaceuticals is experiencing unprecedented growth, driven by the rise of nuclear medicine and the arrival of major new pharmaceutical players. To meet this demand, new CDMO (Contract Development and Manufacturing Organization) lines dedicated to radio-medicine are emerging....
The Lifecycle of Radiopharmaceuticals: From Research to Clinical Use

The Lifecycle of Radiopharmaceuticals: From Research to Clinical Use

Radiopharmaceuticals are drugs that contain radionuclides.

They are primarily used for two main purposes: diagnostic procedures and treatment assessments through imaging. The radiation detected by nuclear medicine cameras helps doctors observe and analyse how the human body functions.

Additionally, they serve therapeutic purposes, as the emitted radiation can specifically target cancerous or diseased cells. Although therapeutic use currently represents only about 10% of radiopharmaceutical applications, this practice is rapidly expanding.

France © 2026 - Lemer Pax